Loading patent…
AssigneeSumitomo Dainippon Pharma Oncology, Inc.
InventorsKoc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
Estimating the term…
Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
A method for increasing PKM2 activity in the provision of decreased tumorigenicity in a subject in need thereof, the method comprising:
Dependencies are inferred from the claim text.